Search Results - "Bjerke, Roger M."

Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers by Hagemann, Urs B, Ellingsen, Christine, Schuhmacher, Joachim, Kristian, Alexander, Mobergslien, Anne, Cruciani, Véronique, Wickstroem, Katrine, Schatz, Christoph A, Kneip, Christoph, Golfier, Sven, Smeets, Roger, Uran, Steinar, Hennekes, Hartwig, Karlsson, Jenny, Bjerke, Roger M, Ryan, Olav B, Mumberg, Dominik, Ziegelbauer, Karl, Cuthbertson, Alan S

“…Targeted thorium-227 conjugates (TTC) represent a new class of molecules for targeted alpha therapy (TAT). Covalent attachment of a 3,2-HOPO chelator to an…”
Get full text

Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model by Wickstroem, Katrine, Karlsson, Jenny, Ellingsen, Christine, Cruciani, Véronique, Kristian, Alexander, Hagemann, Urs B, Bjerke, Roger M, Ryan, Olav B, Linden, Lars, Mumberg, Dominik, Brands, Michael, Cuthbertson, Alan

“…Targeted thorium-227 conjugates (TTCs) represent a novel class of therapeutic radiopharmaceuticals for the treatment of cancer. TTCs consist of the alpha…”
Get full text

Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer by Hammer, Stefanie, Hagemann, Urs B, Zitzmann-Kolbe, Sabine, Larsen, Aasmund, Ellingsen, Christine, Geraudie, Solene, Grant, Derek, Indrevoll, Baard, Smeets, Roger, von Ahsen, Oliver, Kristian, Alexander, Lejeune, Pascale, Hennekes, Hartwig, Karlsson, Jenny, Bjerke, Roger M, Ryan, Olav B, Cuthbertson, Alan S, Mumberg, Dominik

“…Prostate-specific membrane antigen (PSMA) is an attractive target for radionuclide therapy of metastatic castration-resistant prostate cancer (mCRPC)…”
Get full text

In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia by Hagemann, Urs B, Wickstroem, Katrine, Wang, Ellen, Shea, Adam O, Sponheim, Kristine, Karlsson, Jenny, Bjerke, Roger M, Ryan, Olav B, Cuthbertson, Alan S

“…The clinical efficacy of the first approved alpha pharmaceutical, Xofigo (radium-223 dichloride, RaCl ), has stimulated significant interest in the development…”
Get full text

Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met by Burggraaf, Jacobus, Kamerling, Ingrid M C, Gordon, Paul B, Schrier, Lenneke, de Kam, Marieke L, Kales, Andrea J, Bendiksen, Ragnar, Indrevoll, Bård, Bjerke, Roger M, Moestue, Siver A, Yazdanfar, Siavash, Langers, Alexandra M J, Swaerd-Nordmo, Marit, Torheim, Geir, Warren, Madhuri V, Morreau, Hans, Voorneveld, Philip W, Buckle, Tessa, van Leeuwen, Fijs W B, Ødegårdstuen, Liv-Ingrid, Dalsgaard, Grethe T, Healey, Andrew, Hardwick, James C H

“…Intravenous administration of a fluorescently labeled c-Met–binding peptide enables visualization of polyps not detected using white light. Colon cancer…”
Get full text

Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy by Hagemann, Urs B, Wickstroem, Katrine, Hammer, Stefanie, Bjerke, Roger M, Zitzmann-Kolbe, Sabine, Ryan, Olav B, Karlsson, Jenny, Scholz, Arne, Hennekes, Hartwig, Mumberg, Dominik, Cuthbertson, Alan S

“…Targeted α therapy (TAT) offers the potential for the targeted delivery of potent α-particle-emitting radionuclides that emit high linear energy transfer…”
Get more information

Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer by Schatz, Christoph A, Zitzmann-Kolbe, Sabine, Moen, Ingrid, Klotz, Monika, Nair, Shankari, Stargard, Stefan, Bjerke, Roger M, Wickstrøm Biseth, Katrine, Feng, Yuan Zeng, Indrevoll, Bård, Cruciani, Véronique, Karlsson, Jenny, Haendler, Bernard, Nielsen, Carsten H, Alfsen, Maria Z, Hammer, Stefanie, Hennekes, Hartwig, Cuthbertson, Alan, Hagemann, Urs B, Larsen, Aasmund

“…Initially, prostate cancer responds to hormone therapy but eventually resistance develops. Beta emitter-based PSMA (prostate-specific membrane…”
Get full text

A targeted thorium-227 conjugate demonstrates efficacy in preclinical models of acquired drug resistance and combination potential with chemotherapeutics and antiangiogenic therapies by Zitzmann-Kolbe, Sabine, Kristian, Alexander, Zopf, Dieter, Kamfenkel, Claudia, Politz, Oliver, Ellingsen, Christine, Hilbig, Jochen, Juul, Mark U, Fonslet, Jesper, Nielsen, Carsten H, Schatz, Christoph A, Bjerke, Roger M, Cuthbertson, Alan S, Mumberg, Dominik, Hagemann, Urs B

“…Targeted alpha therapies (TATs) are an innovative class of for cancer treatment. The unique mode-of-action of TATs is the induction of deleterious DNA…”
Get full text

An efficient chelator for complexation of thorium-227 by Ramdahl, Thomas, Bonge-Hansen, Hanne T., Ryan, Olav B., Larsen, Åsmund, Herstad, Gunnar, Sandberg, Marcel, Bjerke, Roger M., Grant, Derek, Brevik, Ellen M., Cuthbertson, Alan S.

“…[Display omitted] We present the synthesis and characterization of a highly efficient thorium chelator, derived from the octadentate hydroxypyridinone class of…”
Get full text

Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma by Hagemann, Urs B, Mihaylova, Dessislava, Uran, Steinar R, Borrebaek, Joergen, Grant, Derek, Bjerke, Roger M, Karlsson, Jenny, Cuthbertson, Alan S

“…The cell surface receptor CD70 has been previously reported as a promising target for B-cell lymphomas and several solid cancers including renal cell…”
Get full text

Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344 by Wickstroem, Katrine, Hagemann, Urs B., Kristian, Alexander, Ellingsen, Christine, Sommer, Anette, Ellinger-Ziegelbauer, Heidrun, Wirnitzer, Uta, Hagelin, Else-Marie, Larsen, Aasmund, Smeets, Roger, Bjerke, Roger M., Karlsson, Jenny, Ryan, Olav B., Wengner, Antje M., Linden, Lars, Mumberg, Dominik, Cuthbertson, Alan S.

“…Fibroblast growth factor receptor 2 (FGFR2) has been previously reported to be overexpressed in several types of cancer, whereas the expression in normal…”
Get full text

Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model by Karlsson, Jenny, Hagemann, Urs B, Cruciani, Véronique, Schatz, Christoph A, Grant, Derek, Ellingsen, Christine, Kristian, Alexander, Katoozi, Shirin, Mihaylova, Dessislava, Uran, Steinar R, Suominen, Mari, Bjerke, Roger M, Ryan, Olav B, Cuthbertson, Alan

“…Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-30% of breast cancers but has low expression in normal tissue, making it attractive for…”
Get full text

Synergistic Effect of a Mesothelin-Targeted 227 Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models by Wickstroem, Katrine, Hagemann, Urs B, Cruciani, Véronique, Wengner, Antje M, Kristian, Alexander, Ellingsen, Christine, Siemeister, Gerhard, Bjerke, Roger M, Karlsson, Jenny, Ryan, Olav B, Linden, Lars, Mumberg, Dominik, Ziegelbauer, Karl, Cuthbertson, Alan S

“…Targeted Th conjugates (TTCs) represent a new class of therapeutic radiopharmaceuticals for targeted α-therapy. They comprise the α-emitter Th complexed to a…”
Get full text

Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models by Wickstroem, Katrine, Hagemann, Urs B, Cruciani, Véronique, Wengner, Antje M, Kristian, Alexander, Ellingsen, Christine, Siemeister, Gerhard, Bjerke, Roger M, Karlsson, Jenny, Ryan, Olav B, Linden, Lars, Mumberg, Dominik, Ziegelbauer, Karl, Cuthbertson, Alan S

“…Targeted 227Th conjugates (TTCs) represent a new class of therapeutic radiopharmaceuticals for targeted α-therapy. They comprise the α-emitter 227Th complexed…”
Get full text

Abstract 640: New models of breast and lung cancer bone metastases for preclinical efficacy testing by Suominen, Mari I., Hagemann, Urs B., Konkol, Yvonne, Bernoulli, Jenni, Fagerlund, Katja M., Bjerke, Roger M., Karlsson, Jenny, Halleen, Jussi M., Cuthbertson, Alan

“…Introduction Clinically, bone is a very common site of metastatic spread in many cancers. In breast, and in particular cases of advanced estrogen receptor…”
Get full text

Identification of the Protein Target of Myelin-Binding Ligands by Immunohistochemistry and Biochemical Analyses by Bajaj, Anshika, LaPlante, Nicole E., Cotero, Victoria E., Fish, Kenneth M., Bjerke, Roger M., Siclovan, Tiberiu, Tan Hehir, Cristina A.

“…The ability to visualize myelin is important in the diagnosis of demyelinating disorders and the detection of myelin-containing nerves during surgery. The…”
Get full text

Abstract 591: A novel high energy alpha-pharmaceutical: In vitro and in vivo potency of a mesothelin-targeted thorium-227 conjugate (TTC) in a model of bone disease by Hagemann, Urs B., Hagelin, Else-Marie, Wickstroem, Katrine, Sponheim, Kristine, Smeets, Roger, Karlsson, Jenny, Bjerke, Roger M., Suominen, Mari I., Konkol, Yvonne, Bernoulli, Jenni, Rissanen, Jukka, Halleen, Jussi, Oedegaardstuen, Liv-Ingrid, Cuthbertson, Alan

“…Mesothelin (MSLN) is a 40 kDa membrane-anchored glycoprotein, involved in mediating cell-cell adhesion, metastatic spread, promotion of cell proliferation and…”
Get full text

Abstract 3937: MSLN-TTC (BAY 2287411) demonstrates increased activity in comparison to standard of care chemotherapy in models of acquired drug resistance by Hagemann, Urs B., Zitzmann-Kolbe, Sabine, Kristian, Alexander, Sperl, Carolyn, Schatz, Christoph A., Bjerke, Roger M., Cuthbertson, Alan S., Hennekes, Hartwig, Ziegelbauer, Karl, Mumberg, Dominik

“…Mesothelin (MSLN)-targeted thorium conjugate (MSLN-TTC; BAY 2287411) is a targeted alpha therapy consisting of the MSLN-targeting antibody anetumab, covalently…”
Get full text

Abstract 2257: Targeted thorium-227 conjugates demonstrate synergistic activity in combination with PD-L1 inhibitors by Hagemann, Urs B., Lejeune, Pascale, Bartnitzky, Lisa, Stadelmann, Kathleen, Cruciani, Veronique, Bjerke, Roger M., Berndt, Sandra, Kamfenkel, Claudia, Brand, Manuela, Steinbach, Manuela, Stargard, Stefan, Schatz, Christoph A., Karlsson, Jenny, Hennekes, Hartwig, Cuthbertson, Alan S., Mumberg, Dominik

“…Targeted thorium-227 conjugates (TTCs) represent a new class of targeted alpha therapy (TAT). TTCs consist of an antigen targeting moiety, which is covalently…”
Get full text

Abstract 3726: Preclinical activity of PSMA-TTC (BAY 2315497) in combination with androgen receptor antagonists in prostate cancer models by Hammer, Stefanie, Hagemann, Urs B., Zitzmann-Kolbe, Sabine, Larsen, Aasmund, Ellingsen, Chrstine, Ahsen, Oliver von, Karlsson, Jenny, Bjerke, Roger M., Ryan, Olav B., Lejeune, Pascale, Hennekes, Hartwig, Cuthbertson, Alan, Mumberg, Dominik

“…Targeted alpha therapy (TAT) agents are able to deliver high linear energy transfer alpha-radiation selectively to tumors. The PSMA targeted thorium-227…”
Get full text